Owkin is an (AI) and precision medicine company that builds best-in-class predictive biomedical AI models and robust data sets.
Owkin connects life sciences companies with world-class academic researchers and hospitals to share deep medical insights for drug discovery and development.
Owkin was co-founded in France in 2016 by Thomas Clozel and Gilles Wainrib. The company is headquartered in New York, with offices in Paris and Nantes, France.
Owkin uses federated learning and breakthrough collaborative AI technology to enable partners to unlock siloed datasets while protecting patient privacy and securing proprietary data.
Owkin has created a unique research platform, and a portfolio of AI models and solutions. Owkin Loop is the foundation of Owkin’s research platform: it connects medical researchers with high-quality datasets from leading academic research centers around the world.
Owkin's HealthChain and MELLODDY ate two Owkin led federated learning consortia fuelling unprecedented collaboration in academic research and drug discovery, respectively. Owkin works with the most prominent cancer centers and pharmaceutical companies in Europe and the US.
Owkin is backed by GV, Sanofi, F-Prime Capital, Bpifrance Large Venture, Cathay Innovation, Mubadala Capital, Eight Roads, and others. The company raised $180M in a new round on Nov 18, 2021. This brings Owkin's total funding to $324.1M to date. The latest round valued the company at over $1B post-money.